Aim:

ST segment elevated myocardial infarction (STEMI) is regarded as a type of acute coronary syndrome. However, the mortality of STEMI patients is substantial. Asymmetric dimethylarginine (ADMA) is the major inhibitor of nitric oxide biosynthesis in humans. Studies have shown that increased ADMA levels are associated with endothelial dysfunction and increased atherogenesis. It is aimed to show the relationship between ADMA and prognosis of STEMI.

Materials and Methods:

The study population was 45 (40 male, 5 female) patients with a diagnosis of STEMI, who underwent primary percutaneous coronary intervention (PCI). Demographic data, blood tests, medical history, data related to interventions, in-hospital and out-hospital follow-up of the patients were recorded. Ten cc of blood samples were collected following sheat application. ADMA levels were studied by ELISA kit.

Results:

The follow-up period was 42.837±14.343 months. The mean age was 52.4±7.8. Only significant relation was observed between ADMA levels and heart rate (p=0.025). Other relations with demographic data, risk factors for STEMI, follow-up events such as major adverse cardiovascular events, heart failure, target vessel revascularization, reinfarction, ongoing myocardial ischemia, in-hospital events, intervention artery, type of intervention, Pre-TIMI, ejection fraction, use of tirofiban, anterior or inferior MI were not statistically significant (p>0.05). Although, a positive relation was observed between ADMA levels and chronic heart failure, it was not significant.

Conclusion:

Although, there was a relation with heart failure, the only significant relation was found between ADMA levels and heart rate. Further studies with greater number of participants should be performed for drawing strict conclusions.

Keywords: ADMA, STEMI, 42 months follow-up, mortality and morbidity